• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 15-12G filed by Alpine Immune Sciences Inc.

    5/30/24 9:12:26 AM ET
    $ALPN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALPN alert in real time by email
    15-12G 1 d835572d1512g.htm 15-12G 15-12G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 15

     

     

    CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION

    UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

    OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)

    OF THE SECURITIES EXCHANGE ACT OF 1934.

    Commission File Number: 001-37449

     

     

    ALPINE IMMUNE SCIENCES, INC.

    (Exact name of registrant as specified in its charter)

     

     

    188 East Blaine Street, Suite 200

    Seattle, WA 98102

    Telephone: (206) 788-4545

    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

    Common stock, $0.001 par value per share

    (Title of each class of securities covered by this Form)

    None

    (Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

     

     

    Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

     

    Rule 12g-4(a)(1)

      ☒

    Rule 12g-4(a)(2)

      ☐

    Rule 12h-3(b)(1)(i)

      ☒

    Rule 12h-3(b)(1)(ii)

      ☐

    Rule 15d-6

      ☐

    Rule 15d-22(b)

      ☐

    Approximate number of holders of record as of the certification or notice date: One holder

    Pursuant to the requirements of the Securities Exchange Act of 1934, Alpine Immune Sciences, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

     

    Date: May 30, 2024     Alpine Immune Sciences, Inc.
        By:  

    /s/ Jonathan Biller

        Name:   Jonathan Biller
        Title:   Secretary

     

     

     

    Get the next $ALPN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ALPN

    DatePrice TargetRatingAnalyst
    4/9/2024$55.00Buy
    Guggenheim
    2/15/2024$44.00Outperform
    Wolfe Research
    10/18/2023$18.00Buy
    Berenberg
    10/17/2023$18.00Buy
    Berenberg
    10/5/2023$19.00Outperform
    RBC Capital Mkts
    6/26/2023$14.00Outperform
    Oppenheimer
    1/19/2023$17.00Overweight
    Morgan Stanley
    11/21/2022$15.00Outperform
    SVB Leerink
    More analyst ratings

    $ALPN
    SEC Filings

    See more
    • SEC Form 15-12G filed by Alpine Immune Sciences Inc.

      15-12G - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Filer)

      5/30/24 9:12:26 AM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Alpine Immune Sciences Inc.

      EFFECT - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Filer)

      5/24/24 12:15:07 AM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Alpine Immune Sciences Inc.

      EFFECT - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Filer)

      5/24/24 12:15:33 AM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALPN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Guggenheim initiated coverage on Alpine Immune Sciences with a new price target

      Guggenheim initiated coverage of Alpine Immune Sciences with a rating of Buy and set a new price target of $55.00

      4/9/24 7:38:17 AM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wolfe Research initiated coverage on Alpine Immune Sciences with a new price target

      Wolfe Research initiated coverage of Alpine Immune Sciences with a rating of Outperform and set a new price target of $44.00

      2/15/24 6:19:18 AM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Berenberg initiated coverage on Alpine Immune Sciences with a new price target

      Berenberg initiated coverage of Alpine Immune Sciences with a rating of Buy and set a new price target of $18.00

      10/18/23 7:51:16 AM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALPN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Frazier Life Sciences Appoints Biotech Innovators Mitchell H. Gold and Stanford L. Peng as Venture Partners

      Frazier Life Sciences (FLS), a longstanding investment firm focused on innovative therapeutics, today announced the appointments of Mitchell H. Gold, M.D., and Stanford L. Peng, M.D., Ph.D., as Venture Partners. "We believe Mitch and Stanford bring exceptional leadership and experience that will elevate our ability to create and nurture breakthrough biopharmaceutical companies," said Jamie Topper, M.D., Ph.D., Managing Partner at FLS. "Mitch's history of building transformative companies, his relentless pursuit of scientific excellence and his proven ability to identify transformative scientific and investment opportunities make him a valuable addition to our team. Similarly, Stanford's p

      1/9/25 8:00:00 AM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Attovia Therapeutics Announces Election of Mitchell Gold and Angie You to Board of Directors

      FREMONT, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Attovia Therapeutics today announced the election of Mitchell H. Gold, M.D., and Angie You, Ph.D., as independent members of its Board of Directors. Drs. Gold and You are seasoned biotech executives and experienced board members who bring decades of industry leadership experience, including early- and late-stage therapeutic development and commercialization. "I am delighted to welcome Mitch and Angie to the team. They are industry leaders with a proven track record of success in building both public and private biopharma companies. As Attovia looks toward our next stage of growth and drives our mission of bringing forward first-in-c

      7/9/24 7:30:00 AM ET
      $ALPN
      $ORIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alpine Immune Sciences Reports First Quarter 2024 Financial Results

      Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today reported financial results for the first quarter ended March 31, 2024. On April 10, 2024, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) and Alpine announced that the companies had entered into a definitive agreement under which Vertex will acquire Alpine for $65 per share in cash. The transaction was unanimously approved by both the Vertex and Alpine Boards of Directors and is anticipated to close in the second quarter of 2024. First Quarter 2024 Financial Results Cash Position and Runway: As of March

      5/9/24 4:00:00 PM ET
      $ALPN
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care